DUBLIN--(BUSINESS WIRE)--Sep 14, 2018--The "Cedar Pollen Allergy - Pipeline Review, H2 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Cedar Pollen Allergy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cedar Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Cedar Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Companies Featured

Astellas Pharma Inc. F. Hoffmann-La Roche Ltd. REGiMMUNE Corp. Stallergenes Greer PLC

Key Topics Covered

1. Introduction

2. Report Coverage

3. Cedar Pollen Allergy - Overview

4. Cedar Pollen Allergy - Therapeutics Development

5. Pipeline Overview

6. Cedar Pollen Allergy - Therapeutics Assessment

7. Cedar Pollen Allergy - Companies Involved in Therapeutics Development

8. Cedar Pollen Allergy - Drug Profiles

9. Cedar Pollen Allergy - Dormant Projects

10. Cedar Pollen Allergy - Discontinued Products

11. Cedar Pollen Allergy - Product Development Milestones

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hddxkq/cedar_pollen?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180914005379/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Allergy Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/14/2018 11:25 AM/DISC: 09/14/2018 11:25 AM